Safety Study of MGAH22 in HER2-positive Carcinomas
Is a
Allocation Type
Non-Randomized
0
Participating Facility
Health Conditions in Trial
Intervention Model
Single Group Assignment
0
Intervention Name
margetuximab
0
Interventional Trial Phase
Phase 1
0
Interventional Trial Purpose
Treatment
0
Intervention Type
Biological
0
Last Updated
October 19, 2022
0
Masking Type
None (Open Label)
0
Primary Completion Date
June 14, 2022
0
Trial Recruitment Size
66
0
Trial Sponsor
Clinical Trial Start Date
2010
0
Study Completion Date
June 14, 2022
0
Clinical Trial Study Type
Interventional
0
NCT Number
Official Name
A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available
0
Official Website
Find more entities like Safety Study of MGAH22 in HER2-positive Carcinomas
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.